Claims
- 1. An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, or solvate derivative thereof; wherein;R1 is the group —(L1)—R11, where, —(L1)— is —(CH2)— and R11 is C7-C20 alkyl, C7-C20 haloalkyl, C7-C20 alkenyl, C7-C20 alkynyl, or a carbocyclic radical; R2 is —CH3 or C2H5; R3 is —C(O)—C(O)—NH2; R4 is the group —(La)-(acylsulfonamide group) where —(La)— is —O—CH2— and the acylsulfonamide group is —C(O)—CH—S(O)(O)—R81 and R81 is —CF3, CH3 or C2H5; R5 is hydrogen; and R6 and R7 are hydrogen, or a carbocyclic radical.
- 2. A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.
- 3. A method of inhibiting sPLA2 mediated release of fatty acid which comprises contacting sPLA2 with an therapeutically effective amount of indole compound as claimed in claim 1.
- 4. A method of treating a mammal, including a human, to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises administration to said mammal of at least one indole compound as claimed in claim 1 in a pharmaceutically effective amount.
- 5. A indole compound represented by the formula.
- 6. An indole compound selected from the group consisting of:1-benzyl-2-ethyl-4-methanesulfonamidoylmethyloxy-indole-3-glyoxylamide; and 1-benzyl-2-ethyl-4-trifluoromethanesulfonamidoylmethyloxy-indole-3-glyoxylamide.
Parent Case Info
This application claims the benefit of U.S. Provisional Application 60/095,109 filed Aug. 3, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US99/17460 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/07591 |
2/17/2000 |
WO |
A |
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5578634 |
Bach et al. |
Nov 1996 |
A |
5641800 |
Bach et al. |
Jun 1997 |
A |
5654326 |
Bach et al. |
Aug 1997 |
A |
5684034 |
Bach et al. |
Nov 1997 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/095109 |
Aug 1998 |
US |